| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Tomas Palecek, Jitka Honzikova, Helena Poupetova, Hana Vlaskova, Petr Kuchynka, Lubor Golan, Sudheera Magage, Ales Linhar. Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). Journal of inherited metabolic disease. vol 37. issue 3. 2015-02-20. PMID:24173410. |
a number of studies have already investigated the prevalence of fabry disease (fd) in adult patients with unexplained left ventricular hypertrophy (lvh) with rates varying from 0 % up to 12 % reflecting referral and gender bias as well as differences in diagnostic methodology. |
2015-02-20 |
2023-08-12 |
Not clear |
| Christiane Drechsler, Benjamin Schmiedeke, Markus Niemann, Daniel Schmiedeke, Johannes Krämer, Irina Turkin, Katja Blouin, Andrea Emmert, Stefan Pilz, Barbara Obermayer-Pietsch, Frank Weidemann, Frank Breunig, Christoph Wanne. Potential role of vitamin D deficiency on Fabry cardiomyopathy. Journal of inherited metabolic disease. vol 37. issue 2. 2015-01-21. PMID:24141790. |
patients with fabry disease frequently develop left ventricular (lv) hypertrophy and renal fibrosis. |
2015-01-21 |
2023-08-12 |
Not clear |
| Anita C Boyd, Queenie Lo, Kerry Devine, Michel C Tchan, David O Sillence, Norman Sadick, David A B Richards, Liza Thoma. Left atrial enlargement and reduced atrial compliance occurs early in Fabry cardiomyopathy. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. vol 26. issue 12. 2014-07-16. PMID:24094560. |
fabry disease is associated with left ventricular hypertrophy (lvh) and myocardial fibrosis. |
2014-07-16 |
2023-08-12 |
Not clear |
| Miriam Shanks, Richard B Thompson, Ian D Paterson, Brendan Putko, Aneal Khan, Alicia Chan, Harald Becher, Gavin Y Oudi. Systolic and diastolic function assessment in fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. vol 26. issue 12. 2014-07-16. PMID:24125876. |
fabry cardiomyopathy is characterized by progressive left ventricular hypertrophy (lvh) associated with diastolic dysfunction and is the most common cause of death in fabry disease (fd). |
2014-07-16 |
2023-08-12 |
human |
| Dominique P Germain, Frank Weidemann, Ademola Abiose, Manesh R Patel, Marta Cizmarik, J Alexander Cole, Dana Beitner-Johnson, Karelle Benistan, Gustavo Cabrera, Joel Charrow, Ilkka Kantola, Ales Linhart, Kathy Nicholls, Markus Niemann, C Ronald Scott, Katherine Sims, Stephen Waldek, David G Warnock, Jörg Strotman. Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry. Genetics in medicine : official journal of the American College of Medical Genetics. vol 15. issue 12. 2014-07-14. PMID:23703683. |
the aim of this study was to evaluate the progression of left ventricular hypertrophy in untreated men with fabry disease and to assess the effects of agalsidase-β (recombinant human α-galactosidase a) on left ventricular hypertrophy. |
2014-07-14 |
2023-08-12 |
human |
| Jeffrey B Geske, Hayan Jouni, Marie C Aubry, Bernard J Gers. Fabry disease with resting outflow obstruction masquerading as hypertrophic cardiomyopathy. Journal of the American College of Cardiology. vol 63. issue 17. 2014-06-24. PMID:24632283. |
fabry disease with resting outflow obstruction masquerading as hypertrophic cardiomyopathy. |
2014-06-24 |
2023-08-12 |
Not clear |
| María C Saccheri, Tomás F Cianciulli, Jorge A Lax, Juan A Gagliardi, Guillermo L Cáceres, Alejandra E Quarin, Isaac Kisinovsky, Paula A Rozenfeld, Ricardo C Reisi. Two-dimensional speckle tracking echocardiography for early detection of myocardial damage in young patients with Fabry disease. Echocardiography (Mount Kisco, N.Y.). vol 30. issue 9. 2014-06-04. PMID:23600802. |
fabry disease (fd) is characterized by left ventricular hypertrophy (lvh). |
2014-06-04 |
2023-08-12 |
human |
| Wim Terryn, Gert Deschoenmakere, Jan De Keyser, Wouter Meersseman, Wim Van Biesen, Brigitte Wuyts, Dimitri Hemelsoet, Hilbert Pascale, Julie De Backer, An De Paepe, Bruce Poppe, Raymond Vanholde. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. International journal of cardiology. vol 167. issue 6. 2014-04-22. PMID:22805550. |
prevalence of fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. |
2014-04-22 |
2023-08-12 |
Not clear |
| Wim Terryn, Gert Deschoenmakere, Jan De Keyser, Wouter Meersseman, Wim Van Biesen, Brigitte Wuyts, Dimitri Hemelsoet, Hilbert Pascale, Julie De Backer, An De Paepe, Bruce Poppe, Raymond Vanholde. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. International journal of cardiology. vol 167. issue 6. 2014-04-22. PMID:22805550. |
patients with fabry disease (fd) develop progressive left ventricular hypertrophy (lvh). |
2014-04-22 |
2023-08-12 |
Not clear |
| Kazutoshi Mawatari, Hideo Yasukawa, Toyoharu Oba, Takanobu Nagata, Tadayasu Togawa, Takahiro Tsukimura, Sachiko Kyogoku, Hideki Ohshima, Tomoko Minami, Yusuke Sugi, Hitoshi Sakuraba, Tsutomu Imaizum. Screening for Fabry disease in patients with left ventricular hypertrophy. International journal of cardiology. vol 167. issue 3. 2014-04-02. PMID:23168011. |
screening for fabry disease in patients with left ventricular hypertrophy. |
2014-04-02 |
2023-08-12 |
Not clear |
| Aris Anastasakis, Efstathios Papatheodorou, Alexandros Klavdios Sterioti. Fabry disease and cardiovascular involvement. Current pharmaceutical design. vol 19. issue 33. 2014-04-01. PMID:23448453. |
fabry disease should be included in the differential diagnosis algorithm of idiopathic hypertrophy. |
2014-04-01 |
2023-08-12 |
Not clear |
| Richard B Thompson, Kelvin Chow, Aneal Khan, Alicia Chan, Miriam Shanks, Ian Paterson, Gavin Y Oudi. T₁ mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circulation. Cardiovascular imaging. vol 6. issue 5. 2013-11-14. PMID:23922004. |
t₁ mapping with cardiovascular mri is highly sensitive for fabry disease independent of hypertrophy and sex. |
2013-11-14 |
2023-08-12 |
Not clear |
| Zaheer Yousef, Perry M Elliott, Franco Cecchi, Brigitte Escoubet, Ales Linhart, Lorenzo Monserrat, Mehdi Namdar, Frank Weideman. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. European heart journal. vol 34. issue 11. 2013-09-05. PMID:22736678. |
left ventricular hypertrophy in fabry disease: a practical approach to diagnosis. |
2013-09-05 |
2023-08-12 |
Not clear |
| Dániel Czuriga, Walter J Paulus, István Czuriga, István Édes, Zoltán Papp, Attila Borbél. Cellular mechanisms for diastolic dysfunction in the human heart. Current pharmaceutical biotechnology. vol 13. issue 13. 2013-06-28. PMID:22280428. |
diastolic abnormalities have been described in the senescent heart, in heart failure with preserved ejection fraction (hfpef), in diabetic cardiomyopathy, in aortic valve stenosis (avs), in hypertrophic cardiomyopathy (hcm), as well as in fabry disease (fd), however, exact cellular and molecular alterations behind the diastolic deterioration in these diseases are not yet completely characterized. |
2013-06-28 |
2023-08-12 |
human |
| Gregory A Grabowsk. Gaucher disease and other storage disorders. Hematology. American Society of Hematology. Education Program. vol 2012. 2013-06-27. PMID:23233555. |
examples include age-related neurodegenerative diseases (eg, parkinson disease and gaucher disease), idiopathic hypertrophic myocardiopathies, stroke and renal failure (eg, fabry disease), and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (nafld/nash) and atherosclerosis (eg, lysosomal acid lipase deficiencies). |
2013-06-27 |
2023-08-12 |
Not clear |
| James O Burton, John P Dormer, Helen E Binns, Warren P Pickerin. Sometimes when you hear hoof beats, it could be a zebra: consider the diagnosis of Fabry disease. BMC nephrology. vol 13. 2013-05-24. PMID:22849389. |
fabry disease is an x-linked lysosomal storage disorder that results from a deficiency of the enzyme α-galactosidase a. fabry disease is present in 4-5% of men with unexplained left ventricular hypertrophy or cryptogenic stroke. |
2013-05-24 |
2023-08-12 |
Not clear |
| E J Langereis, I E T van den Berg, D J J Halley, B J H M Poorthuis, F M Vaz, J H J Wokke, G E Linthors. Considering Fabry, but Diagnosing MPS I: Difficulties in the Diagnostic Process. JIMD reports. vol 9. 2013-02-25. PMID:23430557. |
recent studies have indicated that a proportion of patients with renal failure, left ventricular hypertrophy, or cryptogenic stroke have sequence variants in their agal a gene (fabry disease), which has resulted in an increase in diagnostic activities for this disorder. |
2013-02-25 |
2023-08-12 |
Not clear |
| Andrea Frustaci, Matteo Antonio Russo, Cristina Chiment. Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy. Human pathology. vol 44. issue 1. 2013-02-04. PMID:22939960. |
histology showed changes consistent/compatible with hypertrophic cardiomyopathy in 124 patients: myocardial storage disease in 18 due to fabry disease in 12 and glycogen-storage disease in 6 and myocardial infiltrative disease in 9 because of amyloidosis in 7 and sarcoidosis in 2. |
2013-02-04 |
2023-08-12 |
Not clear |
| Manish Motwani, Sanjay Banypersad, Peter Woolfson, Stephen Walde. Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Molecular genetics and metabolism. vol 107. issue 1-2. 2013-01-29. PMID:22704481. |
although left ventricular hypertrophy (lvh) in fabry disease (fd) can improve with enzyme-replacement therapy (ert), the response is difficult to predict. |
2013-01-29 |
2023-08-12 |
Not clear |
| Gerald Mundigler, Martina Gaggl, Georg Heinze, Senta Graf, Manfred Zehetgruber, Natalija Lajic, Till Voigtländer, Christine Mannhalter, Raute Sunder-Plassmann, Eduard Paschke, Günter Fauler, Gere Sunder-Plassman. The endocardial binary appearance ('binary sign') is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy. European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology. vol 12. issue 10. 2012-08-27. PMID:21857019. |
the endocardial binary appearance ('binary sign') is an unreliable marker for echocardiographic detection of fabry disease in patients with left ventricular hypertrophy. |
2012-08-27 |
2023-08-12 |
Not clear |